Results from HPS2-THRIVE Study of TREDAPTIVE™ (extended-release niacin/laropiprant) Presented at American College of Cardiology Scientific Sessions
Dateline City:
SAN FRANCISCO
SAN FRANCISCO--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that researchers from the Clinical Trial Service Unit at
Oxford University presented results from the HPS2-THRIVE (Heart Protection
Study 2-Treatment of HDL to Reduce the Incidence
of Vascular Events) study of TREDAPTIVEā¢(extended-release
niacin/laropiprant) during a late-breaking clinical trials session at
the American College of Cardiology 62nd Annual Scientific
Sessions (abstract 300-14).
Language:
English
Contact HTML:
MerckMedia:Pamela Eisele, 908-423-5042Skip Irvine, 267-305-5397orInvestors:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Latest News Source Type: news
More News: Cardiology | Clinical Trials | Heart | Merck | Niacin | Niaspan | Oxford University | Pharmaceuticals | Study | Vitamin B3